Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2015

01.12.2015 | Original Article

Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients

verfasst von: Ping Liu, Ying Wang, Lina Tong, Yan Xu, Weihao Zhang, Zhi Guo, Hong Ni

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine whether the elevated preoperative plasma D-dimer levels show correlation with chemoresistance and poor prognosis in serous ovarian cancer patients.

Methods

Preoperative plasma D-dimer levels were measured in 125 patients with primary serous ovarian cancer (SOC).The correlations of plasma D-dimer levels with clinicopathological features, chemotherapeutic response, and survival outcome were further analyzed. Kaplan–Meier estimates were used to compute the survival functions and were compared using log-rank tests. Cox proportional-hazard regression analysis was used to evaluate the effects of D-dimer on progression-free survival (PFS) and overall survival (OS), controlling for potential confounding factors.

Results

The median follow-up period was 49 (range 5–85) months. Elevated plasma D-dimer levels were positively associated with advanced FIGO stage (P = 0.010), residual tumor size (P = 0.017), the presence of malignant ascites (P = 0.028), increased serum CA125 level (P = 0.014), and neo-adjuvant chemotherapy (P = 0.008). The patients with elevated plasma D-dimer levels had significantly higher chemoresistance rates (56.41 %) compared to the normal plasma D-dimer levels (20.93 %). Additionally, it was found by the univariate analysis that elevated plasma D-dimer levels were closely related with a low 5-year PFS rate (28.21 vs 52.33 %, P = 0.002) and a poor 5-year OS (30.77 vs 63.95 %, P < 0.001). However, after adjustment for other factors, high plasma D-dimer levels were only closely correlated with a poor 5-year OS (HR 1.901, 95 % CI 1.021–3.540; P = 0.043).

Conclusions

Elevated preoperative plasma D-dimer levels were associated with chemoresistance and poor disease outcome in serous ovarian cancer patients. Further validation of this easily available parameter as a promising prognostic biomarker for patients with SOC in prospective studies should be encouraged.
Literatur
4.
Zurück zum Zitat Feigenberg T, Clarke B, Virtanen C et al (2014) Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int 2014:367103. doi:10.1155/2014/367103 PubMedCentralPubMed Feigenberg T, Clarke B, Virtanen C et al (2014) Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int 2014:367103. doi:10.​1155/​2014/​367103 PubMedCentralPubMed
6.
Zurück zum Zitat Gadducci A, Cosio S, Conte PF, Genazzani AR (2005) Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 55:153–166. doi:10.1016/j.critrevonc.2005.03.003 CrossRefPubMed Gadducci A, Cosio S, Conte PF, Genazzani AR (2005) Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 55:153–166. doi:10.​1016/​j.​critrevonc.​2005.​03.​003 CrossRefPubMed
9.
Zurück zum Zitat Ferrigno D, Buccheri G, Ricca I (2001) Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 17:667–673CrossRefPubMed Ferrigno D, Buccheri G, Ricca I (2001) Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 17:667–673CrossRefPubMed
10.
Zurück zum Zitat Editorial (1986) Haemostatic abnormalities and malignant disease. Lancet 1:303–304 Editorial (1986) Haemostatic abnormalities and malignant disease. Lancet 1:303–304
12.
Zurück zum Zitat Seitz R, Rappe N, Kraus M et al (1993) Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 4:249–254CrossRefPubMed Seitz R, Rappe N, Kraus M et al (1993) Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 4:249–254CrossRefPubMed
13.
Zurück zum Zitat De Buyzere M, Philippe J, Duprez D et al (1993) Coagulation system activation and increase of D-dimer levels in peripheral arterial occlusive disease. Am J Hematol 43:91–94CrossRefPubMed De Buyzere M, Philippe J, Duprez D et al (1993) Coagulation system activation and increase of D-dimer levels in peripheral arterial occlusive disease. Am J Hematol 43:91–94CrossRefPubMed
19.
Zurück zum Zitat Stender MT, Larsen TB, Sorensen HT, Thorlacius-Ussing O (2012) Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost 10:2027–2031. doi:10.1111/j.1538-7836.2012.04887.x CrossRefPubMed Stender MT, Larsen TB, Sorensen HT, Thorlacius-Ussing O (2012) Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost 10:2027–2031. doi:10.​1111/​j.​1538-7836.​2012.​04887.​x CrossRefPubMed
20.
Zurück zum Zitat Inanc M, Er O, Karaca H et al (2013) D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer. J BUON 18:391–397PubMed Inanc M, Er O, Karaca H et al (2013) D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer. J BUON 18:391–397PubMed
21.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed
23.
Zurück zum Zitat Iversen LH, Thorlacius-Ussing O (2002) Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 87:402–408PubMed Iversen LH, Thorlacius-Ussing O (2002) Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 87:402–408PubMed
28.
Zurück zum Zitat Mego M, Karaba M, Minarik G et al (2015) Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J 21:155–160. doi:10.1111/tbj.12388 CrossRefPubMed Mego M, Karaba M, Minarik G et al (2015) Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J 21:155–160. doi:10.​1111/​tbj.​12388 CrossRefPubMed
29.
Zurück zum Zitat Man YN, Wang YN, Hao J et al (2015) Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer 25:24–32. doi:10.1097/IGC.0000000000000303 CrossRefPubMed Man YN, Wang YN, Hao J et al (2015) Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer 25:24–32. doi:10.​1097/​IGC.​0000000000000303​ CrossRefPubMed
35.
Metadaten
Titel
Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients
verfasst von
Ping Liu
Ying Wang
Lina Tong
Yan Xu
Weihao Zhang
Zhi Guo
Hong Ni
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2015
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2900-y

Weitere Artikel der Ausgabe 6/2015

Cancer Chemotherapy and Pharmacology 6/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.